Stock Financial Ratios


CTIC / CTI BioPharma Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price3.50
Volume247,000.00
Market Cap ($M)146.21
Enterprise Value ($M)28.11
Book Value ($M)13.32
Book Value / Share0.48
Price / Book4.40
NCAV ($M)23.20
NCAV / Share0.83
Price / NCAV2.04
Income Statement (mra) ($M)
Revenue57.41
EBITDA-49.16
Net Income-52.95
Balance Sheet (mrq) ($M)
Cash & Equivalents52.80
Cash / Share1.89
Assets65.53
Liabilities37.12
Quick Ratio1.34
Current Ratio1.37
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-2.49
Return on Assets (ROA)-0.83
Return on Equity (ROE)-3.98
Identifiers and Descriptors
CUSIP12648L106
Central Index Key (CIK)891293
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
12648L906
12648L601
12648L956
Share Statistics
Common Shares Outstanding (M)42.97
Scoring Models
Piotroski F Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Deferred Income Tax Liabilities Per Share0.00
Assets Per Share2.34
Inventory Per Share0.02
Property Plant And Equipment Gross Per Share0.00
Inventory Raw Materials Per Share0.00
Accounts Receivable Per Share0.01
Liabilities Per Share1.33
Liabilities Current Per Share0.94
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Equity Per Share1.22
Cash Per Share1.89
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Assets Current Per Share2.06
Accumulated Depreciation And Depletion Per Share0.00
Property Plant And Equipment Net Per Share0.09
Inventory Work In Progress Per Share0.00
Debt Per Share0.28
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.25
Treasury Stock Per Share0.00
Assets Other Non Current Per Share0.20
Liabilities And Stock Equity Per Share2.34
Cash And Equivalents Per Share1.89
Intangibles Per Share0.00
Property Plant And Equipment Per Share0.09
Inventory Finished Goods Per Share0.01
Goodwill Per Share0.00
Current Portion Of Long Term Debt Per Share0.28
Minority Interest Per Share-0.20
Retained Earnings Per Share-78.72
Liabilities Other Non Current Per Share0.11

Related News Stories

Your Daily Pharma Scoop: Adamas's Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

2018-01-19 seekingalpha
Today, we will Adamas Pharmaceuticals (ADMS) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease (PD) patients. (210-1)

Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

2018-01-19 seekingalpha
Today we will Admas Pharmaceuticals' (ADMS) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease (PD) patients. (210-0)

BRIEF-CTI BioPharma to receive $10 mln milestone payment for Trisenox

2018-01-18 reuters
* CTI BIOPHARMA - ‍TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM TEVA PHARMACEUTICAL INDUSTRIES RELATED TO U.S. FDA APPROVAL OF TRISENOX​ Source text for Eikon: Further company coverage: (11-0)

CTI BioPharma Loses Strength As The Company Faces Sharp Revenue Decline

2017-12-20 seekingalpha
CTI BioPharma Corp. (NASDAQ:CTIC) stock showed a steady decline this year, on the back of several setbacks suffered by the company. The company reported steady decline in its revenue in the third quarter while its NDA for its potential blockbuster drug Pacritinib had to be withdrawn. While there had been some positive developments as the European Commission accepted its marketing application for Pacritinib, the stock does not seem to have bottomed out yet and therefore not ready for an investment. (11-0)

BRIEF-CTI Biopharma Corp Says Co Entered Into A Loan And Security Agreement​

2017-11-28 reuters
* CTI BIOPHARMA CORP - ‍ON NOVEMBER 28, 2017, CTI BIOPHARMA CORP ENTERED INTO A LOAN AND SECURITY AGREEMENT​ (11-1)

CUSIP: 12648L106